은 상처 드레싱 시장 : 제품 유형, 최종사용자, 창상 유형, 유통 채널별 - 세계 예측(2025-2032년)
Silver Wound Dressing Market by Product Type, End User, Wound Type, Distribution Channel - Global Forecast 2025-2032
상품코드 : 1840718
리서치사 : 360iResearch
발행일 : 2025년 09월
페이지 정보 : 영문 199 Pages
 라이선스 & 가격 (부가세 별도)
US $ 3,939 ₩ 5,696,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다. 온라인 플랫폼에서 1년 동안 보고서를 무제한으로 다운로드할 수 있으며, 정기적으로 업데이트되는 정보도 이용할 수 있습니다. (연 3-4회 정도 업데이트)
US $ 4,249 ₩ 6,145,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF 및 Excel 보고서를 동일기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다. 온라인 플랫폼에서 1년 동안 보고서를 무제한으로 다운로드할 수 있으며, 정기적으로 업데이트되는 정보도 이용할 수 있습니다. (연 3-4회 정도 업데이트)
US $ 5,759 ₩ 8,329,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF 및 Excel 보고서를 동일 기업 내 동일 지역 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다. 온라인 플랫폼에서 1년 동안 보고서를 무제한으로 다운로드할 수 있으며, 정기적으로 업데이트되는 정보도 이용할 수 있습니다. (연 3-4회 정도 업데이트)
US $ 6,969 ₩ 10,079,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다. 온라인 플랫폼에서 1년 동안 보고서를 무제한으로 다운로드할 수 있으며, 정기적으로 업데이트되는 정보도 이용할 수 있습니다. (연 3-4회 정도 업데이트)


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

은 상처 드레싱 시장은 2032년까지 연평균 복합 성장률(CAGR) 14.65%로 93억 9,000만 달러에 이를 것으로 예측됩니다.

주요 시장 통계
기준 연도 : 2024년 31억 4,000만 달러
추정 연도 : 2025년 36억 달러
예측 연도 : 2032년 93억 9,000만 달러
CAGR(%) 14.65%

은 상처 드레싱이 현대 상처 치료의 임상적 요구, 재료 혁신, 진화하는 증거 요건과 어떻게 교차하는지를 간략하게 소개합니다.

은 상처 드레싱은 임상 효과와 재료 과학의 독특한 교차점에 위치하여 현대 상처 관리의 주요 과제에 대한 광범위한 항균 보호 기능을 제공합니다. 이러한 상처 드레싱은 이온성 은 또는 나노입자 형태를 이용하여 상처 부위의 미생물 군집 형성을 억제하는 동시에 습도 균형과 치유를 촉진하는 환경을 지원합니다. 은 드레싱 재료는 항균성 프로파일로 인해 표준 상처 관리 프로토콜이 어려운 복잡한 급성 손상이나 만성 궤양과 같이 감염 위험이 높은 상처에 선택되는 경우가 많습니다.

현재 임상의와 조달팀은 은 드레싱 재료의 항균 성능뿐만 아니라 생체 적합성, 삼출물 대응성, 착용 용이성, 환자의 편안함 등을 평가했습니다. 한편, 드레싱재 매트릭스, 서방형 플랫폼, 점착 기술의 발전으로 제품의 차별화가 진행되어 다양한 상처 유형에 대한 보다 타겟화된 치료가 가능해졌습니다. 규제 당국의 정밀한 조사와 증거 요건 또한 제품 개발의 우선순위를 강력한 임상 검증과 시판 후 조사로 전환하고 있으며, 엄격한 비교 연구의 필요성을 강조하고 있습니다.

임상계가 항균제 스튜어드십을 강조하는 가운데, 실버 드레싱의 역할은 감염 관리와 내성 위험 감소의 균형을 맞추기 위해 재조정되고 있습니다. 결과적으로 제조업체와 의료 시스템은 은 드레싱 재료가 효과적이고 적절한 도구로 남아 있기 때문에 제품 설계, 임상 증거 생성 및 처방 통합을 조정해야 합니다.

기술 통합, 공급망 강인성, 규제 엄격성, 지속가능성에 대한 기대 등 은 상처치료제 생태계를 형성하는 중요한 변화 트렌드

은 상처 드레싱을 둘러싼 환경은 임상적 기대, 기술 융합, 의료 전반에 걸친 시스템적 압력으로 인해 변화의 물결이 밀려오고 있습니다. 항균제 스튜어드십과 환자 중심적 결과를 중시하는 등 새로운 임상적 우선순위가 등장함에 따라, 설계자들은 항균제 활성을 국소적으로 지속시키고 전신 노출을 최소화하기 위해 은의 전달 메커니즘을 개선해야 할 필요성이 대두되고 있습니다. 동시에, 센서가 장착된 드레싱 재료 및 원격 상처 모니터링 플랫폼과 같은 디지털 건강 도구와의 통합은 드레싱 재료의 기능적 범위를 수동적 보호에서 임상 의사 결정에 정보를 제공하는 능동적 데이터 생성 구성 요소로 확장하고 있습니다.

공급망의 불안정성과 원자재 조달의 어려움은 제조업체들이 공급처를 다변화하고 단일 공급처에 대한 의존도를 피하기 위해 국내 생산 능력을 모색하면서 탄력성 전략에 박차를 가하고 있습니다. 환경적 지속가능성 또한 주변을 배려하는 것에서 주류에 대한 기대치로 전환하여 재활용 가능한 기판, 은 부하 감소, 보다 친환경적인 제조 공정으로 기술 혁신을 촉진하고 있습니다. 규제 측면도 동시에 진화하고 있으며, 클레임 입증, 추적성, 시장 출시 후 증거에 대한 감시가 강화되고, 제품 개발 타임라인과 경쟁 역학이 재구성되고 있습니다.

그 결과, 우수한 임상적 근거, 측정 가능한 임상적 가치를 더하는 통합 기술, 연속성과 컴플라이언스를 보장하는 견고한 공급망 관행의 삼위일체가 경쟁의 전장을 정의하게 되었습니다. 이러한 요소를 갖출 수 있는 기업은 점점 더 결과 중심의 헬스케어 환경에서 임상의의 요구와 의료기관의 조달 기준을 충족시킬 수 있는 최적의 위치에 서게 될 것입니다.

2025년 미국의 관세 조치로 인해 은 상처 드레싱 공급망에서 조달, 제조 비상 대응 계획, 조달 관행이 어떻게 바뀌었는가?

2025년 미국의 새로운 관세 조치의 도입은 은 상처 드레싱 재료의 전체 밸류체인에 누적 영향을 미쳐 조달 전략, 가격 책정, 재고 관리에 영향을 미쳤습니다. 수입에 의존하는 제조업체와 유통업체는 원자재 및 완제품의 육지 비용 상승에 직면하여 공급업체와의 계약 및 적시 보충 모델을 즉시 재검토해야 했습니다. 이에 대응하기 위해 많은 기업들이 공급업체 다변화를 가속화하고, 관세 인상과 리드타임의 장기화에 따른 영향을 완화하기 위해 재고 헤지를 진행하였습니다.

병원과 의료 네트워크의 경우, 조달 팀이 임상 가용성을 유지하면서 단가 변동을 관리하기 위해 구매 패턴을 재조정하여 다운스트림에 영향을 미쳤습니다. 그 결과, 단기적인 조달 마찰이 발생하여 통관 규정 준수 및 관세 분류와 관련된 관리 업무량이 증가하였습니다. 동시에 일부 제조업체는 이를 계기로 니어쇼어링 및 지역 제조 옵션을 모색하여 국경 간 관세 위험에 대한 노출을 줄이고 보다 예측 가능한 납기를 확보하기 위해 현지 생산 능력에 투자했습니다.

또한, 관세를 계기로 제품의 표준화와 제조 가능한 설계가 다시 한 번 강조되고 있습니다. 규제 부서와 품질 부서가 긴밀히 협력하여 변경 관리 프로세스를 간소화하고, 제품의 무결성을 유지하면서 신속한 제조 전환을 가능하게 했습니다. 요약하면, 2025년 관세는 임상 공급과 상업적 연속성을 유지하기 위해 공급망 민첩성, 현지화 전략, 비즈니스 우발상황 대비 계획으로 방향을 전환하도록 유도했습니다.

제품 형태, 임상 적응증, 의료 환경, 유통 채널을 연계한 심층적인 세분화 인사이트를 통해 타겟에 맞는 개발 및 상업화 전략을 수립할 수 있습니다.

은 상처 드레싱의 개발, 상업적, 임상적 전략을 조정하기 위해서는 제품 및 채널 세분화를 이해하는 것이 필수적입니다. 제품 유형에 따라 알긴산, 필름, 폼, 하이드로콜로이드, 하이드로겔 드레싱 재료로 나뉘며, 폼은 다시 폴리우레탄 폼과 실리콘 폼으로 세분화되며, 각각 고유한 수분 처리 특성과 접착 특성을 제공하여 임상 선택에 영향을 미칩니다. 제공합니다. 각 제품군은 각기 다른 상처 부위의 요구를 충족시키며, 은 공급에 대한 설계 선택은 기판의 흡수 프로파일, 적합성, 착용 시간을 반영해야 합니다.

목차

제1장 서문

제2장 조사 방법

제3장 주요 요약

제4장 시장 개요

제5장 시장 인사이트

제6장 미국 관세의 누적 영향 2025

제7장 AI의 누적 영향 2025

제8장 은 상처 드레싱 시장 : 제품 유형별

제9장 은 상처 드레싱 시장 : 최종사용자별

제10장 은 상처 드레싱 시장 : 상처 유형별

제11장 은 상처 드레싱 시장 : 유통 채널별

제12장 은 상처 드레싱 시장 : 지역별

제13장 은 상처 드레싱 시장 : 그룹별

제14장 은 상처 드레싱 시장 : 국가별

제15장 경쟁 구도

LSH
영문 목차

영문목차

The Silver Wound Dressing Market is projected to grow by USD 9.39 billion at a CAGR of 14.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.14 billion
Estimated Year [2025] USD 3.60 billion
Forecast Year [2032] USD 9.39 billion
CAGR (%) 14.65%

A concise introduction to how silver-based wound dressings intersect clinical needs, material innovation, and evolving evidence requirements in contemporary wound care

Silver-based wound dressings occupy a unique intersection of clinical efficacy and material science, providing broad-spectrum antimicrobial protection that addresses key challenges in contemporary wound management. These dressings leverage ionic silver or nanoparticulate forms to inhibit microbial colonization at wound sites while supporting moisture balance and a conducive healing environment. Due to their antimicrobial profile, silver dressings are frequently selected for wounds with elevated infection risk, including complex acute injuries and chronic ulcers that challenge standard wound care protocols.

Clinicians and procurement teams now evaluate silver dressings not only on antimicrobial performance but also on biocompatibility, exudate handling, ease of application, and patient comfort. Meanwhile, ongoing advances in dressing matrices, controlled-release platforms, and adhesive technologies have refined product differentiation, enabling more targeted therapy across diverse wound types. Regulatory scrutiny and evidence requirements have also shifted product development priorities toward robust clinical validation and post-market surveillance, reinforcing the need for rigorous comparative studies.

As the clinical community emphasizes antimicrobial stewardship, the role of silver dressings is being recalibrated to balance infection control with resistance risk mitigation. Consequently, manufacturers and health systems must align product design, clinical evidence generation, and formulary integration to ensure silver dressings remain an effective, appropriate tool in modern wound-care pathways.

Critical transformative trends reshaping the silver wound dressing ecosystem including technology integration, supply chain resilience, regulatory rigor, and sustainability expectations

The landscape for silver wound dressings is experiencing a wave of transformative shifts driven by clinical expectations, technology fusion, and systemic pressures across healthcare delivery. Emerging clinical priorities, including a sharper focus on antimicrobial stewardship and patient-centered outcomes, are prompting designers to refine silver delivery mechanisms so that antimicrobial activity is localized, sustained, and dosed to minimize systemic exposure. At the same time, integration with digital health tools-such as sensor-enabled dressings and remote wound-monitoring platforms-is expanding the functional remit of dressings from passive protection to active data-generating components that inform clinical decision-making.

Supply chain volatility and raw material sourcing challenges have accelerated strategies for resilience, with manufacturers diversifying suppliers and exploring domestic production capabilities to avoid single-source dependencies. Environmental sustainability has also moved from peripheral consideration to mainstream expectation, pushing innovation toward recyclable substrates, reduced silver loadings, and greener manufacturing processes. Regulatory pathways are evolving concurrently, with increased scrutiny on claims substantiation, traceability, and post-market evidence, which has reshaped product development timelines and competitive dynamics.

Consequently, the competitive battleground is now defined by a triad of superior clinical evidence, integrated technologies that add measurable clinical value, and robust supply chain practices that assure continuity and compliance. Companies that can align these elements will be best positioned to meet clinician needs and institutional procurement criteria in an increasingly outcome-driven healthcare environment.

How the 2025 United States tariff measures reshaped sourcing, manufacturing contingency planning, and procurement practices across the silver wound dressing supply chain

The introduction of new tariff measures in the United States during 2025 has exerted a cumulative effect across the silver wound dressing value chain, influencing sourcing strategies, pricing dynamics, and inventory practices. Import-dependent manufacturers and distributors faced increased landed costs for raw materials and finished goods, prompting immediate reassessments of supplier contracts and just-in-time replenishment models. In response, many organizations accelerated supplier diversification and advanced inventory hedging to mitigate the impact of elevated customs duties and longer lead times.

Hospitals and healthcare networks experienced downstream implications as procurement teams recalibrated purchase patterns to manage unit-cost variability while preserving clinical availability. This created short-term procurement friction and increased administrative workload associated with customs compliance and tariff classification. Simultaneously, some manufacturers saw this as an impetus to explore nearshoring and regional manufacturing options, investing in localized production capacity to reduce exposure to cross-border tariff risk and to obtain more predictable delivery timelines.

Moreover, the tariffs prompted renewed emphasis on product standardization and design for manufacturability so that production could be shifted across facilities without significant requalification burden. Regulatory and quality teams worked closely to streamline change-control processes to enable rapid manufacturing shifts while maintaining product integrity. In sum, the tariffs of 2025 catalyzed a reorientation toward supply chain agility, localization strategies, and operational contingency planning to sustain clinical supply and commercial continuity.

Deep segmentation insights that connect product form, clinical indication, care setting, and distribution channels to inform targeted development and commercialization strategies

Understanding product and channel segmentation is essential to align development, commercial, and clinical strategies for silver wound dressings. Based on Product Type, the competitive set spans Alginate, Film, Foam, Hydrocolloid, and Hydrogel dressings, with Foam further subdivided into Polyurethane Foam and Silicone Foam, each offering distinct moisture-handling and adhesion characteristics that influence clinical selection. Each product family addresses different wound-bed needs, and design choices around silver delivery must reflect the substrate's absorption profile, conformability, and wear time.

Based on End User, demand patterns vary among Clinics, Homecare, and Hospitals, with Hospitals further categorized into Government Hospitals and Private Hospitals; institutional purchasing rules, formulary procedures, and procurement cycles differ significantly across these endpoints, shaping adoption speed and product mix. Hospitals often prioritize standardized systems-level protocols and bulk procurement, while homecare emphasizes ease of use and patient comfort, and clinics balance procedure-driven needs with cost-efficiency.

Based on Wound Type, clinical indications fall into Acute Wounds and Chronic Wounds, where the Acute Wounds cohort is further specified as Burn Wounds, Surgical Wounds, and Traumatic Wounds, and the Chronic Wounds cohort is further differentiated as Diabetic Foot Ulcers, Pressure Ulcers, and Venous Leg Ulcers. These distinctions are critical because dressing selection depends on etiology, exudate level, infection risk, and expected healing trajectory, and they dictate trials and evidence required to support claims for specific indications.

Based on Distribution Channel, products reach end users through Hospital Pharmacies, Online, and Retail Pharmacies, with Online distribution divided into Direct To Consumer and Ecommerce Platforms, and Retail Pharmacies further split into Chain Pharmacies and Independent Pharmacies. Each channel imposes its own commercial imperatives: hospital pharmacy channels emphasize contract compliance and procurement efficiency, online channels prioritize customer experience and digital marketing, and retail pharmacy channels focus on inventory turnover and point-of-care recommendations. Understanding these nested segmentation layers enables strategic prioritization of product formats, evidence generation, and channel-specific marketing approaches to optimize adoption across the care continuum.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated adoption pathways, regulatory approaches, and commercial tactics

Regional dynamics exert strong influence on clinical adoption, regulatory expectations, and commercial execution for silver wound dressings. In the Americas, clinical protocols emphasize evidence-based utilization and infection-control practices across acute and chronic care settings, and the purchasing environment is shaped by integrated health systems and large group purchasing organizations that demand contractual clarity and demonstrable clinical value. This region also leads in adoption of digital health adjuncts that complement topical therapies.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with diverse reimbursement frameworks and procurement modalities. Health systems in this region may prioritize cost-effectiveness and lifecycle environmental impact alongside clinical performance, creating opportunities for differentiated value propositions that highlight sustainability and long-term clinical outcomes. Local manufacturing and regional distribution partnerships frequently play a pivotal role in ensuring market access across heterogeneous regulatory jurisdictions.

In Asia-Pacific, rapid healthcare infrastructure expansion, growing homecare capabilities, and high-volume acute care demands are shaping adoption pathways. The region demonstrates significant innovation uptake, particularly where local manufacturers adapt product profiles to regional wound-care practices and cost sensitivities. Across all regions, differences in clinical practice patterns, purchasing behavior, and regulatory expectations necessitate tailored evidence generation and commercial strategies to achieve meaningful penetration and sustained utilization.

Corporate strategies and competitive differentiators that combine clinical evidence, manufacturing scale, partnerships, and intellectual property to secure leadership in wound-care solutions

Competitive positioning in the silver wound dressing domain is determined by a combination of clinical evidence, manufacturing scale, intellectual property, and commercial agility. Market leaders and specialized wound-care firms are investing in incremental product improvements such as refined silver release kinetics, improved adhesion systems, and matrices that better manage exudate while preserving tissue viability. Meanwhile, nimble startups and material-science innovators are introducing alternative silver formulations and composite dressings that target specific clinical gaps.

Strategic collaborations between device manufacturers, academic centers, and clinicians are accelerating the clinical validation cycle and enabling more robust real-world evidence generation. Partnerships with contract manufacturers and regional distributors help established firms extend reach while maintaining consistent quality and compliance. At the same time, companies that prioritize lifecycle management-through iterative product upgrades, post-market surveillance, and targeted clinical studies-are better able to defend formulary positions and to demonstrate longitudinal value to institutional buyers.

Intellectual property strategies, including patents on delivery systems and unique substrate compositions, remain critical for protecting differentiated offerings. Ultimately, organizations that align R&D investment, clinical evidence programs, and supply chain capabilities create durable competitive advantage and are more effective in translating product innovation into sustained clinical and commercial adoption.

Actionable strategic recommendations for companies to synchronize product innovation, clinical evidence, supply chain resilience, sustainability, and commercial execution in wound care

Industry leaders should adopt a multi-dimensional strategy that synchronizes product innovation, clinical validation, supply chain resilience, and commercial execution. Prioritize development of silver delivery systems that demonstrate targeted antimicrobial action with controlled release and minimal cytotoxicity, and couple those technical improvements with clinical programs that deliver indication-specific evidence across acute and chronic wound types. This evidence-driven approach will support product inclusion in standardized care pathways and institutional formularies.

Strengthen supply chain architecture by diversifying raw material sources, qualifying alternate production sites, and investing in nearshoring where feasible to reduce exposure to tariff-induced cost fluctuations and logistic disruptions. Concurrently, integrate sustainability goals into product design and manufacturing to align with institutional procurement priorities and to reduce lifecycle environmental footprint. From a commercial standpoint, tailor go-to-market approaches by end-user segment and distribution channel, offering clinician education for hospital and clinic adoption while optimizing packaging, instructions for use, and direct-to-consumer messaging for homecare channels.

Finally, embed digital health capabilities where they create measurable clinical benefits, such as remote monitoring of wound healing progress or adherence tracking. Forge cross-functional partnerships with clinicians, regulatory experts, and payers early in the development cycle to de-risk market entry and to align evidence packages with reimbursement requirements. By orchestrating these strategic levers, leaders can convert technical advantages into sustained clinical adoption and institutional procurement support.

An integrated research methodology combining primary clinical engagement, secondary evidence synthesis, and rigorous triangulation to produce actionable and validated insights

The research underpinning these insights employed an integrated methodology combining primary stakeholder engagement, exhaustive literature review, and systematic data validation to ensure analytical rigor and practical relevance. Primary research included structured interviews with clinicians, wound-care nurses, procurement officers, regulatory specialists, and product development leaders to capture frontline perspectives on clinical needs, adoption barriers, and procurement drivers. These qualitative inputs were used to shape hypothesis-driven inquiry and to identify high-priority areas for deeper investigation.

Secondary research encompassed review of peer-reviewed clinical studies, regulatory guidance documents, standards for medical device classification, and technical white papers on silver delivery technologies. Information from regulatory filings and product labeling informed assessments of claims substantiation and evidence maturity. Triangulation between primary and secondary sources ensured consistency of findings and helped to reveal gaps where further clinical validation may be required.

Data quality assurance incorporated cross-validation of interview-derived insights with documented clinical recommendations and regulatory benchmarks, and stakeholder feedback loops were used to refine interpretations. The methodology prioritized transparency in data sources and a reproducible approach to synthesizing clinical, technical, and commercial signals into strategic recommendations suitable for operationalization by product, clinical, and commercial teams.

A concise conclusion emphasizing the strategic imperatives that will determine which organizations successfully advance silver wound dressing adoption and clinical impact

In sum, silver wound dressings continue to represent a strategically important class of products for infection-prone wounds, but their future relevance depends on aligning material science innovation with evolving clinical and purchasing expectations. Advances in silver delivery systems, coupled with improved wound-contact substrates and adhesive technologies, are enhancing clinical utility, while digital adjuncts and sustainability-focused manufacturing are shaping new vectors of differentiation.

The 2025 tariff environment underscored the necessity of supply chain agility and localization strategies, accelerating investments in diversified sourcing and manufacturing flexibility. Segmentation analysis clarifies that product design, evidence generation, and channel strategy must be tailored by product type, end-user setting, wound etiology, and distribution route to achieve meaningful adoption. Region-specific dynamics further require nuanced regulatory and commercial approaches.

Consequently, companies that integrate robust clinical evidence, resilient operations, and targeted commercial strategies will be best positioned to navigate current headwinds and to capture opportunities in advancing wound-care practices. The strategic alignment of R&D, regulatory, manufacturing, and commercial functions will drive the next wave of sustained clinical adoption and institutional acceptance.

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Silver Wound Dressing Market, by Product Type

9. Silver Wound Dressing Market, by End User

10. Silver Wound Dressing Market, by Wound Type

11. Silver Wound Dressing Market, by Distribution Channel

12. Silver Wound Dressing Market, by Region

13. Silver Wound Dressing Market, by Group

14. Silver Wound Dressing Market, by Country

15. Competitive Landscape

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기